Bio Sidus Sa
Clinical trials sponsored by Bio Sidus Sa, explained in plain language.
-
New fabry drug shows promise in small switch study
Disease control CompletedThis phase 3 trial tested a new version of the drug agalsidase beta (AGA BETA BS) in 20 people with Fabry disease who were already stable on the standard drug Fabrazyme. Participants switched to the new drug for 54 weeks to see if it worked just as well. The main goal was to keep…
Phase: PHASE3 • Sponsor: Bio Sidus SA • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New version of fabry drug tested against Brand-Name in healthy volunteers
Knowledge-focused CompletedThis early study tested whether a new version of the enzyme replacement drug agalsidase beta (made by Biosidus) works similarly to the approved drug Fabrazyme. Twenty-four healthy men received a single infusion of one of the two drugs. Researchers measured how the drug moved thro…
Phase: PHASE1 • Sponsor: Bio Sidus SA • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC